Image

An Imaging Study of Polyvascular Disease

An Imaging Study of Polyvascular Disease

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

  1. Establish a multimodality imaging database for PVD, improve the one-stop screening process for early PVD based on artificial intelligence, build a full-cycle control information platform, and promote the construction and standardization of a multidisciplinary co-morbidity and co-management diagnosis and treatment model.
  2. Based on non-invasive, zero-contrast ocular OCTA combined with one-stop CTA imaging of the heart and brain, construct an integrated "eye-heart-brain" early warning model for PVD, and explore a potential non-invasive and convenient early warning system for PVD.
  3. Based on the multi-omics, investigate EVs-mediated intercellular communication network, elucidate the roles and regulatory mechanisms of EVs in the development of PVD, search for potential targets for intervention, and construct an artificial intelligence-based "pan-vascular score" risk assessment system based on the combination of multi-modality imaging and multi-omics biomarkers.

Eligibility

Inclusion Criteria:

Task 1:

  1. Patients with coronary artery disease (≥50% stenosis in any coronary artery on coronary angiography)
  2. Age ≥18 years old
  3. Proposed OCT-IVUS integrated imaging system
  4. able to provide written informed consent prior to the start of any procedures related to the study.

Task 2:

  1. patients with coronary artery disease (coronary angiography reveals ≥50% degree of stenosis in any coronary artery) and patients with stroke or TIA (confirmed by a neurologist)
  2. Age ≥ 18 years
  3. able to provide written informed consent prior to the start of any procedures related to the study.

Exclusion Criteria:

Task 1:

  1. severely tortuous/calcified coronary arteries with anticipated difficulty in completing the OCT-IVUS integrated imaging system
  2. uncontrolled congestive heart failure or acute left heart failure;plan
  3. claustrophobia;
  4. left main stem occlusion;
  5. proposed coronary artery bypass grafting (CABG);
  6. uncontrolled severe ventricular arrhythmia;
  7. active bleeding or severe bleeding tendency;
  8. acute stroke;
  9. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ;
  10. severe renal insufficiency and/or anuria, except in cases where dialysis treatment has been planned;
  11. contraindications to the application of contrast media;
  12. patients who are severely uncooperative due to psychiatric or serious systemic illness;
  13. Patients who, in the opinion of the investigator, are unsuitable for participation in the study.

Task 2:

  1. patients who are unable to comply with the follow-up schedule;
  2. uncontrolled congestive heart failure or acute left heart failure;
  3. patients with a life expectancy of less than 6 months;
  4. left main stem occlusion;
  5. proposed coronary artery bypass grafting (CABG);
  6. uncontrolled severe ventricular arrhythmia;
  7. active bleeding or severe bleeding tendency;
  8. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ;
  9. severe renal insufficiency and/or anuria, except in cases where dialysis treatment has been planned;
  10. contraindications to the application of contrast media;
  11. patients who are severely uncooperative due to psychiatric or serious systemic illness;
  12. patients who, in the opinion of the investigator, are not suitable for participation in the study.

Study details
    Polyvascular Disease

NCT06016608

Harbin Medical University

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.